Double-Blind Study of Topical WBI-1001 Cream on Patients With Psoriasis (WBI-1001-101)
|ClinicalTrials.gov Identifier: NCT00830817|
Recruitment Status : Completed
First Posted : January 28, 2009
Last Update Posted : January 28, 2009
|Condition or disease|
Patients initiated screening within 4 weeks of commencing study treatment. Based on progression of the study, at day 0 patients were assigned to one of six treatment Cohorts. Patients were randomized to treat all areas except the face, scalp, groin and genital areas. Patients in Cohort 1 were treated on one side with a thin layer of active cream and the other with placebo; in the absence of significant AEs by 14 days after the last treatment in the Cohort escalation to the next Cohort was allowed, and each Cohort respectively.
During the treatment period patients visited the study centre weekly for safety, tolerability and efficacy assessment. On these study visit days blood draws were done between 7.00 and 10.00am prior to that morning's application of cream.
The study enrolled healthy male and female patients aged 18-65 y.o. with clinical diagnosis of stable plaque psoriasis for >months affecting a maximum of 6% of BSA with a minimum of 0.5% BSA on each side of the body and a minimum of one plaque at least 2x2 cm on each side excluding elbow and knee.
|Study Type :||Observational|
|Actual Enrollment :||36 participants|
|Observational Model:||Case Control|
|Official Title:||A Randomized, Double-Blind Phase I Study to Evaluate Topically Applied WBI-1001 Cream in Patients With Psoriasis.|
|Study Start Date :||July 2007|
|Actual Primary Completion Date :||April 2008|
|Actual Study Completion Date :||June 2008|
- Evaluate safety and tolerability of topically applied WBI-1001 cream, and to assess the pharmacokinetics based on plasma concentrations [ Time Frame: 35 days ]
- Obtain initial evaluation of efficacy of topically applied WBI-1001 cream in patients with mild to moderate psoriasis. [ Time Frame: 35 days ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00830817
|Innovaderm Research inc.|
|Montreal, Quebec, Canada, H2K 4L5|
|Study Chair:||John m Webster, PhD, D.Sc.||Welichem Biotech Inc.|
|Study Director:||Liren Tang, Ph.D||Welichem Biotech Inc.|